284 related articles for article (PubMed ID: 23610445)
1. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
[TBL] [Abstract][Full Text] [Related]
2. NRF2 Intensifies Host Defense Systems to Prevent Lung Carcinogenesis, but After Tumor Initiation Accelerates Malignant Cell Growth.
Satoh H; Moriguchi T; Saigusa D; Baird L; Yu L; Rokutan H; Igarashi K; Ebina M; Shibata T; Yamamoto M
Cancer Res; 2016 May; 76(10):3088-96. PubMed ID: 27020858
[TBL] [Abstract][Full Text] [Related]
3. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
4. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.
Tao S; Rojo de la Vega M; Chapman E; Ooi A; Zhang DD
Mol Carcinog; 2018 Feb; 57(2):182-192. PubMed ID: 28976703
[TBL] [Abstract][Full Text] [Related]
5. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
6. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
7. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression.
Cicchini M; Buza EL; Sagal KM; Gudiel AA; Durham AC; Feldser DM
Cell Rep; 2017 Feb; 18(8):1958-1969. PubMed ID: 28228261
[TBL] [Abstract][Full Text] [Related]
8. Secretory leukocyte protease inhibitor modulates urethane-induced lung carcinogenesis.
Jan Treda C; Fukuhara T; Suzuki T; Nakamura A; Zaini J; Kikuchi T; Ebina M; Nukiwa T
Carcinogenesis; 2014 Apr; 35(4):896-904. PubMed ID: 24282288
[TBL] [Abstract][Full Text] [Related]
9. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.
Hammoud Z; Tan B; Badve S; Bigsby RM
Endocr Relat Cancer; 2008 Jun; 15(2):475-83. PubMed ID: 18509000
[TBL] [Abstract][Full Text] [Related]
10. The transcriptome of Nrf2-/- mice provides evidence for impaired cell cycle progression in the development of cigarette smoke-induced emphysematous changes.
Gebel S; Diehl S; Pype J; Friedrichs B; Weiler H; Schüller J; Xu H; Taguchi K; Yamamoto M; Müller T
Toxicol Sci; 2010 May; 115(1):238-52. PubMed ID: 20133372
[TBL] [Abstract][Full Text] [Related]
11. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation.
Müller F; Lim JKM; Bebber CM; Seidel E; Tishina S; Dahlhaus A; Stroh J; Beck J; Yapici FI; Nakayama K; Torres Fernández L; Brägelmann J; Leprivier G; von Karstedt S
Cell Death Differ; 2023 Feb; 30(2):442-456. PubMed ID: 36443441
[TBL] [Abstract][Full Text] [Related]
12. [Redox-dependent signaling system Nrf2/are in inflammation].
Men'shikova EB; Tkachev VO; Zenkov NK
Mol Biol (Mosk); 2010; 44(3):389-404. PubMed ID: 20608163
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 and antioxidant defense against CYP2E1 toxicity.
Cederbaum A
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1223-44. PubMed ID: 19671018
[TBL] [Abstract][Full Text] [Related]
14. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
15. Nrf2-activated expression of sulfiredoxin contributes to urethane-induced lung tumorigenesis.
Mishra M; Jiang H; Chawsheen HA; Gerard M; Toledano MB; Wei Q
Cancer Lett; 2018 Sep; 432():216-226. PubMed ID: 29906488
[TBL] [Abstract][Full Text] [Related]
16. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
17. Genomic landscape of chemical-induced lung tumors under Nrf2 different expression levels.
Satoh H; Arai Y; Furukawa E; Moriguchi T; Hama N; Urushidate T; Totoki Y; Kato M; Ohe Y; Yamamoto M; Shibata T
Carcinogenesis; 2022 Aug; 43(7):613-623. PubMed ID: 35561328
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis.
Iida K; Itoh K; Maher JM; Kumagai Y; Oyasu R; Mori Y; Shimazui T; Akaza H; Yamamoto M
Carcinogenesis; 2007 Nov; 28(11):2398-403. PubMed ID: 17602169
[TBL] [Abstract][Full Text] [Related]
19. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
[TBL] [Abstract][Full Text] [Related]
20. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice.
Horio Y; Chen A; Rice P; Roth JA; Malkinson AM; Schrump DS
Mol Carcinog; 1996 Dec; 17(4):217-23. PubMed ID: 8989915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
